Takeda Pharmaceutical Files 6-K with SEC
Ticker: TKPHF · Form: 6-K · Filed: Apr 19, 2024 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Apr 19, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, foreign-private-issuer, routine-update
TL;DR
Takeda filed a 6-K on 4/19/24, standard foreign issuer update. Nothing major.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on April 19, 2024, reporting information as a foreign private issuer. The filing indicates Takeda's principal executive offices are located in Tokyo, Japan, and it is subject to SEC Act of 1934. Takeda is required to file annual reports under Form 20-F.
Why It Matters
This filing provides routine updates for Takeda as a foreign private issuer, ensuring compliance with SEC regulations for investors tracking the company's official disclosures.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain new financial information or significant corporate events.
Key Players & Entities
- Takeda Pharmaceutical Company Limited (company) — Registrant
- 0001395064-24-000029 (filing_id) — Accession Number
- 20240419 (date) — Filing Date
- 001-38757 (company_id) — Commission File Number
- Tokyo, Japan (location) — Principal Executive Offices
FAQ
What type of SEC filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer.
Who is the registrant for this filing?
The registrant is Takeda Pharmaceutical Company Limited.
When was this filing submitted?
The filing was submitted on April 19, 2024.
Where are Takeda's principal executive offices located?
Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, 103-8668, Japan.
Under which SEC Act is Takeda filing this report?
Takeda is filing this report pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Filing Stats: 206 words · 1 min read · ~1 pages · Grade level 14.5 · Accepted 2024-04-19 06:12:47
Filing Documents
- form6k_041924.htm (6-K) — 12KB
- entyvio_approval.htm (EX-99.1) — 21KB
- entyvio_approval001.jpg (GRAPHIC) — 282KB
- entyvio_approval002.jpg (GRAPHIC) — 282KB
- entyvio_approval003.jpg (GRAPHIC) — 236KB
- entyvio_approval004.jpg (GRAPHIC) — 278KB
- entyvio_approval005.jpg (GRAPHIC) — 223KB
- 0001395064-24-000029.txt ( ) — 1826KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date April 19, 2024 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller